Sources: OpenEvidence, an AI search engine for doctors, raised $250M at a $15B valuation, up from $12B in January; it could be open to selling itself

The cost of accessing AI search tools for medical professionals has decreased significantly.

OpenEvidence, an AI search engine for physicians, has secured $250 million in new funding, achieving a $15 billion valuation. This valuation represents a significant increase from its January valuation of $12 billion. The investment was reportedly led by hospital systems and Andreessen Horowitz. The company has raised over $1 billion in the past year, with backing from prominent investors like Thrive Capital, DST, GV, Kleiner Perkins, and Sequoia Capital. OpenEvidence, founded in 2022 and based in Miami, claims its AI search engine is the fastest-growing application for physicians. It states that over two-thirds of U.S. doctors use its diagnostic and treatment advice tool. The company also indicated it may be open to a sale, a move that could offer AI giants a quicker entry into the lucrative healthcare market. Nvidia is an existing investor, and OpenEvidence has integrated with AI tools from Google and Microsoft, and recently partnered with Anthropic. This funding round occurs amidst a broader trend of AI companies, including OpenAI and Anthropic, increasing their focus and development of healthcare-specific products.

The substantial valuation increase for OpenEvidence signals robust investor confidence in AI-driven solutions for specialized professional markets, particularly healthcare. This rapid ascent, coupled with potential openness to acquisition, suggests a consolidation trend where established AI players might acquire specialized startups to accelerate their entry into high-value sectors like medicine. OpenEvidence's existing user base and experience with sensitive medical data present an attractive shortcut for larger entities seeking to expand their healthcare footprint.

The market is witnessing a strategic pivot where AI giants are not just developing foundational models but actively pursuing specialized applications and user bases through acquisitions. This could intensify competition and drive further innovation, but also raise barriers to entry for smaller startups. For physicians, this ecosystem shift may lead to more integrated and potentially more advanced AI tools, though the long-term impact on data privacy and vendor lock-in remains a critical consideration.